0001213900-23-045117.txt : 20230601 0001213900-23-045117.hdr.sgml : 20230601 20230601171925 ACCESSION NUMBER: 0001213900-23-045117 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230601 DATE AS OF CHANGE: 20230601 EFFECTIVENESS DATE: 20230601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Origin Life Sciences, Inc. CENTRAL INDEX KEY: 0001573901 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 273705184 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-483151 FILM NUMBER: 23985690 BUSINESS ADDRESS: STREET 1: 2 RESEARCH WAY STREET 2: THIRD FLOOR CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-250-6000 MAIL ADDRESS: STREET 1: 2 RESEARCH WAY STREET 2: THIRD FLOOR CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: Origin, Inc. DATE OF NAME CHANGE: 20170501 FORMER COMPANY: FORMER CONFORMED NAME: Advanced Plasma Therapies, Inc. DATE OF NAME CHANGE: 20130408 D 1 primary_doc.xml X0708 D LIVE 0001573901 Origin Life Sciences, Inc. 2 RESEARCH WAY THIRD FLOOR PRINCETON NJ NEW JERSEY 08540 (609) 250-6000 DELAWARE Plasma Jet Technologies, Inc. Origin, Inc. Advanced Plasma Therapies, Inc. Corporation true Michael David Preston c/o Origin Life Sciences, Inc. 2 Research Way, Third Floor Princeton NJ NEW JERSEY 08540 Executive Officer Director Chief Executive Officer David Dantzker c/o Origin Life Sciences, Inc. 2 Research Way, Third Floor Princeton NJ NEW JERSEY 08540 Executive Officer Director Chief Medical Officer John Fernandes c/o Origin Life Sciences, Inc. 2 Research Way, Third Floor Princeton NJ NEW JERSEY 08540 Executive Officer Chief Financial Officer Anthony Brampton c/o Origin Life Sciences, Inc. 2 Research Way, Third Floor Princeton NJ NEW JERSEY 08540 Director Victor Micati c/o Origin Life Sciences, Inc. 2 Research Way, Third Floor Princeton NJ NEW JERSEY 08540 Director Jerome Boda Korten c/o Origin Life Sciences, Inc. 2 Research Way, Third Floor Princeton NJ NEW JERSEY 08540 Director Biotechnology Decline to Disclose 06b false 2023-05-30 false true false 25000 None None None None NONE NONE NONE XX Unknown 00000 NY NEW YORK false 850000 500000 350000 Corporation and its stockholders are entering into a private placement offering of: (i) up to 425,000 shares of the Corporation's common stock, par value $0.01 per share, at a price per share of $2.00, for gross proceeds of up to $850,000. false 1 0 0 0 While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false Origin Life Sciences, Inc. /s/ Michael D. Preston Michael D. Preston Chief Executive Officer and Chairman 2023-06-01